Voro and Daiichi Sankyo Forge Alliance for 'Smarter' Cancer Drugs

SAN DIEGO, CA – March 17, 2026 – In a move that signals a continued push toward greater precision in oncology, Voro Therapeutics today announced a research collaboration with global pharmaceutical leader Daiichi Sankyo. The partnership will leverage Voro’s proprietary PrimeBody™ platform to develop a new generation of “masked” antibody-drug conjugates (ADCs), aiming to solve one of the most persistent challenges in cancer therapy: collateral damage to healthy tissue.

The collaboration brings together Voro, a San Diego-based biotechnology innovator, and Daiichi Sankyo, a company widely recognized for its dominance in the ADC field, most notably with its blockbuster drug Enhertu. Together, they will evaluate the potential of Voro's technology to create ADCs that remain inert in the body until they reach the unique microenvironment of a tumor, where they are selectively activated to release their potent cancer-killing payload.

“Unlocking the full potential of highly potent payloads requires a new level of control over where and when activation occurs,” said Ugur Eskiocak, Ph.D., Co-Founder and CEO of Voro Therapeutics, in the official announcement. “We believe this approach has the potential to fundamentally expand the therapeutic index of ADCs. We are excited to collaborate with Daiichi Sankyo, a global leader in ADC innovation with a proven track record of developing transformative medicines for patients.”

The Quest for a More Precise 'Guided Missile'

Antibody-drug conjugates are often described as biological “guided missiles” designed to deliver cytotoxic agents directly to cancer cells. They consist of a monoclonal antibody that targets a specific antigen on tumor cells, a highly potent chemotherapy payload, and a linker that connects the two. While this approach has revolutionized treatment for certain cancers, its effectiveness can be limited by on-target, off-tumor toxicity—where the ADC binds to the same target antigen present on healthy cells, causing significant side effects and limiting the tolerable dose.

Voro Therapeutics' PrimeBody™ platform is designed to address this fundamental problem head-on. The technology adds two key components to a biologic: a proprietary “masking” domain that physically blocks the antibody from binding to its target, and a specialized linker designed to be cleaved by proteases, enzymes that are highly active within the tumor microenvironment but relatively stable in healthy tissues and blood.

In essence, the platform creates a prodrug version of the ADC that circulates harmlessly throughout the body. Only upon entering the chaotic, enzyme-rich environment of a tumor is the linker cut and the mask removed, unleashing the ADC’s full therapeutic power precisely where it is needed. This conditional activation is the key to potentially widening the therapeutic index—the crucial gap between a drug’s effective dose and its toxic dose.

A Strategic Move in a Competitive Field

For Daiichi Sankyo, this collaboration is a strategic maneuver to maintain its leadership position in the fiercely competitive ADC market. The success of Enhertu has not only set a high bar for efficacy but has also spurred a wave of investment and innovation across the industry. Major pharmaceutical players and nimble biotechs alike are racing to develop the next breakthrough ADC platform.

Companies like CytomX Therapeutics, with its Probody® platform, have already demonstrated the clinical potential of protease-activated biologics. By partnering with Voro, Daiichi Sankyo gains access to a differentiated, next-generation masking technology without diverting focus from its own robust internal pipeline. This allows the pharma giant to explore novel approaches that could overcome the limitations of current therapies and secure its footing for the future.

Under the terms of the agreement, Voro will apply its PrimeBody technology to design and characterize masked ADC candidates directed against an undisclosed oncology target chosen by Daiichi Sankyo. While financial details were not disclosed, such early-stage research deals typically involve a combination of upfront payments, research funding, and significant future milestone payments and royalties contingent on development and commercial success. This structure provides validation and non-dilutive capital for Voro while offering its larger partner a de-risked path to a potentially best-in-class technology.

Expanding the Battlefield Against Cancer

The most profound impact of technologies like PrimeBody may be their ability to expand the very definition of a “druggable” cancer target. Many promising antigens are abundantly expressed on tumors but are also present at lower levels on vital, healthy tissues. Targeting these antigens with conventional ADCs is often unfeasible due to the risk of severe, dose-limiting toxicity. A reliable masking technology could render these targets accessible for the first time.

“PrimeBody is designed to potentially provide that level of control through tumor-selective activation and expand the target universe to include antigens historically considered too broadly expressed,” Eskiocak noted.

This promise is supported by Voro's own preclinical work. The company’s lead internal program is a first-in-class, masked CD47 blocker. CD47 is a well-known “don’t eat me” signal that cancer cells use to evade the immune system, but it is also present on red blood cells, making it a notoriously difficult target. Unmasked anti-CD47 antibodies often cause severe anemia and other hematologic toxicities. Voro has stated that its PrimeBody version of the CD47 blocker has demonstrated an improved therapeutic index in preclinical models, mitigating these toxicities while preserving potent anti-tumor activity. This internal success story serves as a powerful proof-of-concept for the platform and was likely a key factor in securing the partnership with Daiichi Sankyo.

The collaboration will now put that platform to the test with a new target, representing a calculated step toward a future where the most powerful cancer drugs can be deployed with unprecedented precision, potentially transforming outcomes for patients across a wide spectrum of malignancies.